ClinicalTrials.gg
Active, not recruitingNCT06717126OCULE-01Updated Jan 16, 2026

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

A Phase 2 interventional study of roginolisib and Investigator choice of standard therapy in Uveal Melanoma and Ocular Melanoma, sponsored by iOnctura. Active, not recruiting at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by iOnctura · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Uveal Melanoma with a site in United Kingdom — 4 open to participants now, 13 under way, 6 of them phase 3. Uveal Melanoma · United Kingdom.

Planned enrollment
16th of 23
85 · median 146
Started
2025
the only one that year
Phase 2
6 of 26
none open now
Primary completion
2027-12
later than 8 of 12 live
Registered
22nd of 26
by date
Lead sponsor
2 of 26
iOnctura

Among the 26 studies in Uveal Melanoma with a site in United Kingdom, this one is the 16th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 2, reaches primary completion later than 8 of the 12 other live ones, and was the 22nd registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

4 of the 26 studies in Uveal Melanoma with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 42 Uveal Melanoma studies recruiting now, 35 (83%) set no upper age limit and 4 (10%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Uveal Melanoma with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma. The main questions it aims to answer are:

Does roginolisib extend overall survival compared to standard treatment? How does dosing of roginolisib impact quality of life compared to standard treatment?

Read the detailed description

A Phase II open-label, randomised, parallel-arm study, which will assess the clinical efficacy of oral roginolisib (IOA 244 [roginolisib hemi-fumarate]) as monotherapy against a control of Investigator´s treatment choice in patients with advanced or metastatic uveal melanoma (UM).

This study will enrol approximately 85 male and female patients aged over 18 years with advanced or metastatic UM, who have progressed following at least 1 prior immunotherapy treatment. The disease must be measurable (i.e., at least 1 measurable lesion) as per RECIST v1.1 by Computerised Tomography (CT) scan or Magnetic Resonance Imaging (MRI).

03

Conditions studied

  • Uveal Melanoma
  • Ocular Melanoma

Keywords

  • Uveal
  • Ocular
  • Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 18 years or older;
  2. or cytologically proven diagnosis of advanced or UM or ocular melanoma (arising from ocular melanocytes regardless of intraocular location)
  3. Patients who have progressed following at least 1 prior immunotherapy treatment for advanced or metastatic UM. For patients who are HLA-A*02:01 positive prior treatment should have included tebentafusp, if available or patients clinically suitable. Patients who have also received prior melphalan hepatic infusion may be included;
  4. Presence of at least one lesion suitable for . Biopsies will be mandatory at Screening and C5D1 (see Sections 8.1.3 and 8.6 for more information);
  5. Presence of at least one as per v1.1. Any lesion that is biopsied cannot be used as a measurable lesion for the purposes of RECIST v1.1 assessments;
  6. performance status of 0 to 1;
  7. Male or female patients of must be willing to use highly effective forms of (refer to APPENDIX 7 for details on highly effective methods of contraception and definitions of women of childbearing potential and of fertile men)
  8. All other relevant medical conditions must be well managed and stable, in the Investigator's opinion, for at least 28 days prior to first dose of roginolisib;
  9. Provision of signed and dated, written prior to any study specific procedures, sampling and analyses.

Exclusion criteria

Exclusion Criteria:

  1. Inability to swallow oral medication;
  2. a). History of a prior Grade 3 or 4 irAE or any grade ocular irAE from prior immunotherapy which did not respond to therapy or resolved with treatment interruptions and returned to at least Grade 1; b). Have not recovered from toxic effect(s) of prior therapy to ≤ Grade 1, other than alopecia or fatigue or neuropathy which must be ≤ Grade 1;
  3. Presence of symptomatic or untreated or CNS metastases that require doses of corticosteroids within the prior 3 weeks to first dose of roginolisib. Patients with brain metastases are eligible if lesions have been treated with localised therapy and there is no evidence of progressive disease for at least 4 weeks prior to the first dose of IMP;
  4. Abnormal liver enzymes defined as:

    1. or AST ≥ 3× (ULN) (≥ 5× ULN in patients with liver );
    2. Total ≥ 1.5 × ULN are excluded unless direct bilirubin is ≤ ULN. If there is no institutional ULN, then direct bilirubin must be \< 40% of total bilirubin to be eligible (except patients with Gilbert syndrome);
  5. Any other out of range laboratory values;
  6. Clinically significant cardiac disease or impaired cardiac function which may limit the patient´s participation in the clinical study. These may include unstable angina (i.e., not responsive to medical intervention), myocardial infarct in last 6 months, prolongation of more than 500 ms;
  7. Evidence of interstitial lung disease or active, non-infectious pneumonitis, pulmonary fibrosis;
  8. Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy at least 1 week prior to the first dose of IMP;
  9. Active virus (HBV) or virus (HCV) infection per institutional protocol;
  10. Malignant disease, other than that being treated in this study (e.g., skin/cutaneous and/or mucosal melanoma). Exceptions to this exclusion include the following: that were treated curatively and have not recurred within 2 years prior to first dose of IMP; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type;
  11. Any medical condition that would, in the Investigator\'s or Sponsor\'s judgment, prevent the patient\'s participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results;
  12. Treatment with anti-tumour medications or drugs within 14 days or 5 half-lives (whichever is longer) of administration of first dose of IMP;
  13. Major surgery within 2 weeks of the first dose of IMP (minimally invasive procedures such as bronchoscopy, tumour , insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary);
  14. Radiotherapy within 4 weeks of the first dose of IMP, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumour mass;
  15. Pregnant, likely to become pregnant, or lactating women.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Arm 1 - Roginolisib 80mg

    IOA-244: 80 mg (corresponding to 72 mg roginolisib) daily

    Drug: roginolisib

  • Active comparator
    Arm 2 - Investigator choice of standard of care

    Investigator´s choice of therapy

    Drug: Investigator choice of standard therapy

  • Experimental
    Arm 3 - Roginolisib 40mg

    IOA-244: 40 mg (corresponding to 36 mg roginolisib) daily

    Drug: roginolisib

Interventions

  • rognolisib

    Also known as: IOA-244

  • DrugInvestigator choice of standard therapy

    Investigator will choose the most appropriate treatment standardly given to patients

06

What researchers measure

Primary outcomes

  1. Overall survival

    To evaluate clinical efficacy of roginolisib as single agent, against Investigator's choice of therapy by assessment of overall survival (OS)

    Time frame: Patients will be followed up for overall survival every 12 weeks, for 96 weeks from last patient enrolled, until their death or end of the study

Secondary outcomes

  1. Progression free survival (PFS)

    PFS measured from the time from the date of the first dose of IMP until the earliest date of disease progression as determined by radiographic/objective disease assessment as per RECIST v1.1

    Time frame: Patients will be followed up for progression free survival every 8 weeks, for 96 weeks from last patient enrolled, until progression of disease, their death or end of the study

  2. Objective response rate (ORR)

    ORR defined as percentage of patients with a Complete Response (CR) or Partial Response (PR)

    Time frame: Every 8 weeks whilst on treatment anticipated to be 52 weeks

  3. Duration of response (DOR)

    DOR defined as the time from the date of first documented response (CR, PR) by RECIST v1.1 until the date of documented progression or death in the absence of disease progression

    Time frame: Every 8 weeks up to 96 weeks from start of treatment

  4. Time to response

    Time to Response is defined as the time from date of first dose of IMP until the date of first documented objective response

    Time frame: Every 8 weeks whilst on treatment anticipated to be 52 weeks

  5. Disease control rate (DCR)

    DCR is defined as the proportion of patients with a Best Objective Response (BOR) of CR or PR or Stable disease (SD) recorded at ≥8 weeks (±1 week),

    Time frame: Every 8 weeks whilst on treatment anticipated to be 52 weeks

  6. Clinical benefit rate (CBR)

    CBR is defined as the proportion of patients with a BOR of CR or PR or SD recorded at Cycle 5 Day 1

    Time frame: Measured at Cycle 5 - approximately 16 weeks from start of dosing

  7. Safety and tolerability

    Assessed by AEs, laboratory parameters, vital signs, physical exam, ECG and ECOG status

    Time frame: Every 4 weeks whilst on treatment anticipated to be 52 weeks

  8. Pharmacokinetics (PK)

    Concentration of roginolisib at pre-dose and steady state levels (including Area under the curve \[AUC\], population PK)

    Time frame: Every 4 weeks for 52 weeks from start of treatment

  9. Safety of 40 vs 80 mg of roginolisib

    Assessed by AEs, laboratory parameters, vital signs, physical exam, ECG and ECOG status

    Time frame: Every 4 weeks whilst on treatment anticipated to be 52 weeks

  10. Health care utilisation

    Assessed by health resource used

    Time frame: Every 4 weeks whilst on treatment anticipated to be 52 weeks

  11. Quality of Life

    Changes in Patient Reported Outcomes (PRO) relative to baseline. Patients to complete EuroQoL Research Foundation EQ-5D-5L Health questionnaire

    Time frame: Every 4 weeks for 52 weeks from start of treatment

  12. Quality of Life

    Changes in Patient Reported Outcomes (PRO) relative to baseline. Patients to complete European Organisation for Research and Treatment of Cancer (EORTC QlQ-C30)

    Time frame: Every 4 weeks for 52 weeks from start of treatment

  13. Quality of Life

    Changes in Patient Reported Outcomes (PRO) relative to baseline. Patients to complete Epworth Sleepiness Scale (ESS) questionnaire

    Time frame: Every 4 weeks for 52 weeks from start of treatment

  14. Quality of Life

    Changes in Patient Reported Outcomes (PRO) relative to baseline. Patients to complete Fatigue Severity Scale (FSS)

    Time frame: Every 4 weeks for 52 weeks from start of treatment

Other outcomes

  1. Circulating Tumour Deoxyribonucleic Acid (ctDNA)

    To assess any treatment-related changes in the pre and on treatment levels of circulating DNA from blood

    Time frame: Every 4 weeks for 52 weeks from start of treatment

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

Of 46 phase 2 interventional studies under Uveal Melanoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Dec 4, 2024
StartActual
Feb 27, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06717126
Lead sponsor
iOnctura
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Feb 27, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jan 16, 2026

Study contacts

Michael Lahn, MD
study director · iOnctura

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roginolisib

Start the discussion